Protalix Historical Financial Ratios

PLX Stock

USD 1.69 0.01 0.60%

Protalix Biotherapeutics is promptly reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.85, Invested Capital of 0.0, Average Payables of 45.2 K or Stock Based Compensation To Revenue of 0.05 will help investors to properly organize and evaluate Protalix Biotherapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

About Protalix Financial Ratios Analysis

Protalix BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Protalix Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Protalix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Protalix Biotherapeutics history.

Protalix Biotherapeutics Financial Ratios Chart

At this time, Protalix Biotherapeutics' Tangible Book Value Per Share is fairly stable compared to the past year. Shareholders Equity Per Share is likely to rise to 0.85 in 2024, whereas Price To Sales Ratio is likely to drop 1.74 in 2024.

Price To Sales Ratio Days Sales Outstanding Average Payables Ev To Sales Inventory Turnover Ev To Free Cash Flow

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Protalix Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Protalix Biotherapeutics sales, a figure that is much harder to manipulate than other Protalix Biotherapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most ratios from Protalix Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Tangible Book Value Per Share is fairly stable compared to the past year. Shareholders Equity Per Share is likely to rise to 0.85 in 2024, whereas Price To Sales Ratio is likely to drop 1.74 in 2024.

	2021	2022	2023	2024 (projected)
Payables Turnover	2.34	3.34	5.32	5.59
Days Of Inventory On Hand	400.83	313.06	302.47	366.4

Payables Turnover Days Of Inventory On Hand

Protalix Biotherapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.2	0.53	0.03	0.48	0.24	-0.16	0.27	-0.2	1.0	0.22	-0.76	0.69	0.22	0.19	-0.43	0.89	-0.39	0.13	-0.76	0.12	0.04	0.36	-0.01	0.14	0.13
Ptb Ratio	-0.2		0.28	-0.01	-0.26	-0.32	0.12	0.01	1.0	-0.2	-0.31	0.04	-0.05	-0.1	0.19	0.19	-0.07	0.23	-0.87	0.04	-0.94	0.51	0.09	0.2	-0.22	-0.87
Days Sales Outstanding	0.53	0.28		0.14	0.25	0.1	0.25	0.18	0.28	0.53	0.09	-0.42	0.47	0.02	-0.18	0.06	0.5	0.14	-0.46	-0.42	-0.33	0.0	-0.11	-0.28	-0.31	-0.46
Book Value Per Share	0.03	-0.01	0.14		0.49	0.61	0.82	0.24	-0.01	0.03	0.63	0.0	0.2	0.51	-0.03	0.72	0.0	0.15	-0.39	0.0	-0.04	-0.7	-0.05	-0.27	-0.1	-0.39
Free Cash Flow Yield	0.48	-0.26	0.25	0.49		0.71	0.25	0.09	-0.26	0.48	0.71	-0.22	0.28	0.26	0.12	0.19	0.33	-0.08	0.06	-0.22	0.11	-0.35	0.17	-0.44	-0.06	0.06
Operating Cash Flow Per Share	0.24	-0.32	0.1	0.61	0.71		0.19	0.39	-0.32	0.24	1.0	-0.09	0.13	0.52	0.08	0.36	0.15	-0.26	0.17	-0.09	0.14	-0.34	0.04	-0.55	0.2	0.17
Average Payables	-0.16	0.12	0.25	0.82	0.25	0.19		0.03	0.12	-0.16	0.2	0.08	0.19	0.23	-0.17	0.75	-0.13	0.53	-0.56	0.08	-0.08	-0.79	-0.17	-0.3	-0.33	-0.57
Capex To Depreciation	0.27	0.01	0.18	0.24	0.09	0.39	0.03		0.01	0.26	0.36	-0.61	0.61	0.14	-0.36	0.3	0.53	-0.14	-0.08	-0.61	-0.24	0.02	-0.35	-0.3	0.01	-0.08
Pb Ratio	-0.2	1.0	0.28	-0.01	-0.26	-0.32	0.12	0.01		-0.2	-0.31	0.04	-0.05	-0.1	0.19	0.19	-0.07	0.23	-0.87	0.04	-0.94	0.51	0.09	0.2	-0.22	-0.87
Ev To Sales	1.0	-0.2	0.53	0.03	0.48	0.24	-0.16	0.26	-0.2		0.22	-0.76	0.69	0.22	0.19	-0.43	0.89	-0.39	0.13	-0.76	0.12	0.04	0.36	-0.01	0.14	0.13
Free Cash Flow Per Share	0.22	-0.31	0.09	0.63	0.71	1.0	0.2	0.36	-0.31	0.22		-0.06	0.1	0.55	0.09	0.37	0.12	-0.28	0.16	-0.06	0.14	-0.35	0.05	-0.53	0.19	0.15
Roic	-0.76	0.04	-0.42	0.0	-0.22	-0.09	0.08	-0.61	0.04	-0.76	-0.06		-0.96	-0.06	0.18	0.17	-0.97	0.25	0.04	1.0	0.08	-0.08	0.01	0.03	0.05	0.04
Inventory Turnover	0.69	-0.05	0.47	0.2	0.28	0.13	0.19	0.61	-0.05	0.69	0.1	-0.96		0.08	-0.27	0.03	0.91	-0.08	-0.15	-0.96	-0.06	-0.15	-0.1	-0.13	-0.14	-0.16
Net Income Per Share	0.22	-0.1	0.02	0.51	0.26	0.52	0.23	0.14	-0.1	0.22	0.55	-0.06	0.08		0.23	0.24	0.08	-0.62	-0.03	-0.06	0.04	-0.26	0.19	0.08	-0.07	-0.03
Days Of Inventory On Hand	0.19	0.19	-0.18	-0.03	0.12	0.08	-0.17	-0.36	0.19	0.19	0.09	0.18	-0.27	0.23		-0.37	-0.06	-0.17	-0.01	0.18	-0.06	0.2	0.97	0.11	0.53	-0.01
Payables Turnover	-0.43	0.19	0.06	0.72	0.19	0.36	0.75	0.3	0.19	-0.43	0.37	0.17	0.03	0.24	-0.37		-0.29	0.29	-0.49	0.17	-0.31	-0.51	-0.48	-0.43	-0.5	-0.49
Capex To Revenue	0.89	-0.07	0.5	0.0	0.33	0.15	-0.13	0.53	-0.07	0.89	0.12	-0.97	0.91	0.08	-0.06	-0.29		-0.29	0.0	-0.97	-0.04	0.11	0.11	-0.03	0.06	0.0
Cash Per Share	-0.39	0.23	0.14	0.15	-0.08	-0.26	0.53	-0.14	0.23	-0.39	-0.28	0.25	-0.08	-0.62	-0.17	0.29	-0.29		-0.41	0.25	-0.12	-0.33	-0.16	-0.25	-0.06	-0.41
Pocfratio	0.13	-0.87	-0.46	-0.39	0.06	0.17	-0.56	-0.08	-0.87	0.13	0.16	0.04	-0.15	-0.03	-0.01	-0.49	0.0	-0.41		0.04	0.83	-0.06	0.05	-0.03	0.37	1.0
Interest Coverage	-0.76	0.04	-0.42	0.0	-0.22	-0.09	0.08	-0.61	0.04	-0.76	-0.06	1.0	-0.96	-0.06	0.18	0.17	-0.97	0.25	0.04		0.08	-0.08	0.01	0.03	0.05	0.04
Capex To Operating Cash Flow	0.12	-0.94	-0.33	-0.04	0.11	0.14	-0.08	-0.24	-0.94	0.12	0.14	0.08	-0.06	0.04	-0.06	-0.31	-0.04	-0.12	0.83	0.08		-0.53	0.05	-0.06	0.33	0.82
Pfcf Ratio	0.04	0.51	0.0	-0.7	-0.35	-0.34	-0.79	0.02	0.51	0.04	-0.35	-0.08	-0.15	-0.26	0.2	-0.51	0.11	-0.33	-0.06	-0.08	-0.53		0.15	0.37	0.11	-0.05
Days Payables Outstanding	0.36	0.09	-0.11	-0.05	0.17	0.04	-0.17	-0.35	0.09	0.36	0.05	0.01	-0.1	0.19	0.97	-0.48	0.11	-0.16	0.05	0.01	0.05	0.15		0.11	0.55	0.05
Income Quality	-0.01	0.2	-0.28	-0.27	-0.44	-0.55	-0.3	-0.3	0.2	-0.01	-0.53	0.03	-0.13	0.08	0.11	-0.43	-0.03	-0.25	-0.03	0.03	-0.06	0.37	0.11		-0.08	-0.03
Roe	0.14	-0.22	-0.31	-0.1	-0.06	0.2	-0.33	0.01	-0.22	0.14	0.19	0.05	-0.14	-0.07	0.53	-0.5	0.06	-0.06	0.37	0.05	0.33	0.11	0.55	-0.08		0.37
Ev To Operating Cash Flow	0.13	-0.87	-0.46	-0.39	0.06	0.17	-0.57	-0.08	-0.87	0.13	0.15	0.04	-0.16	-0.03	-0.01	-0.49	0.0	-0.41	1.0	0.04	0.82	-0.05	0.05	-0.03	0.37

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	0.89	1.68	0.96	1.39	1.83	1.74
Ptb Ratio	(0.69)	(3.91)	(6.08)	(6.24)	3.58	3.4
Days Sales Outstanding	31.37	11.61	32.76	35.14	29.38	27.91
Book Value Per Share	(4.74)	(0.93)	(0.14)	(0.22)	0.5	0.85
Free Cash Flow Yield	(0.41)	(0.25)	(0.32)	(0.39)	(0.0205)	(0.0216)
Operating Cash Flow Per Share	(1.3)	(0.9)	(0.23)	(0.52)	(0.0195)	(0.0205)
Stock Based Compensation To Revenue	0.0153	0.0497	0.0619	0.0438	0.0526	0.05
Capex To Depreciation	0.39	0.5	1.31	0.58	0.96	1.21
Pb Ratio	(0.69)	(3.91)	(6.08)	(6.24)	3.58	3.4
Ev To Sales	1.68	2.42	0.81	1.74	1.88	1.78
Free Cash Flow Per Share	(1.35)	(0.92)	(0.27)	(0.53)	(0.0365)	(0.0384)
Roic	1.02	0.13	(1.09)	(0.72)	0.18	0.19
Inventory Turnover	1.34	0.83	0.91	1.17	1.21	1.15
Net Income Per Share	(1.77)	(0.51)	(0.77)	(0.31)	0.12	0.13
Days Of Inventory On Hand	273.21	439.15	400.83	313.06	302.47	366.4
Payables Turnover	1.68	1.51	2.34	3.34	5.32	5.59
Sales General And Administrative To Revenue	(0.11)	(0.0809)	(0.1)	(0.29)	(0.33)	(0.31)
Research And Ddevelopement To Revenue	0.82	0.61	0.78	0.62	0.26	0.25
Capex To Revenue	0.0115	0.0104	0.038	0.0132	0.0175	0.0167
Cash Per Share	1.2	1.32	1.77	0.46	0.66	0.63
Pocfratio	(2.51)	(4.05)	(3.57)	(2.66)	(91.18)	(95.74)
Interest Coverage	(1.35)	0.19	(2.72)	(5.15)	3.29	3.45
Capex To Operating Cash Flow	(0.0886)	(0.0324)	(0.0251)	(0.14)	(0.87)	(0.83)
Pfcf Ratio	(2.44)	(3.95)	(3.13)	(2.59)	(48.71)	(51.15)
Days Payables Outstanding	217.59	242.4	155.97	109.21	68.61	65.18
Income Quality	1.06	4.0	0.37	1.67	(0.16)	(0.15)
Roe	0.5	0.37	0.55	5.63	0.25	0.24
Ev To Operating Cash Flow	(4.74)	(5.82)	(3.03)	(3.31)	(93.19)	(97.85)
Pe Ratio	(1.85)	(7.1)	(1.08)	(4.45)	14.46	15.18
Return On Tangible Assets	(0.58)	(0.22)	(0.46)	(0.27)	0.0984	0.1
Ev To Free Cash Flow	(4.59)	(5.68)	(2.66)	(3.23)	(49.78)	(52.27)
Earnings Yield	(0.54)	(0.14)	(0.93)	(0.22)	0.0692	0.0726
Net Debt To E B I T D A	(4.96)	10.37	0.29	(1.52)	0.23	0.22
Current Ratio	0.81	0.64	1.86	1.38	1.54	1.46
Tangible Book Value Per Share	(4.74)	(0.93)	(0.14)	(0.22)	0.5	0.85
Receivables Turnover	7.24	11.64	31.45	11.14	10.39	12.42
Graham Number	13.73	3.27	1.54	1.23	1.17	1.11
Shareholders Equity Per Share	(4.74)	(0.93)	(0.14)	(0.22)	0.5	0.85
Debt To Equity	(0.79)	(2.16)	(4.82)	(2.75)	0.65	0.68

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Protalix Historical Financial Ratios

About Protalix Financial Ratios Analysis

Protalix Biotherapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Ev To Sales

Inventory Turnover

Ev To Free Cash Flow

Protalix Biotherapeutics fundamentals Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Interest Coverage	+ 1.0	Roic
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Days Payables Outstanding	+ 0.97	Days Of Inventory On Hand

Interest Coverage	- 0.97	Capex To Revenue
Capex To Revenue	- 0.97	Roic
Interest Coverage	- 0.96	Inventory Turnover
Inventory Turnover	- 0.96	Roic
Capex To Operating Cash Flow	- 0.94	Pb Ratio
Capex To Operating Cash Flow	- 0.94	Ptb Ratio